Dyve Biosciences

Focus: Dyve Biosciences is a topical-focused biotechnology company headquartered in Camarillo, CA, specializing in neurology therapeutics with an early-stage pipeline.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Dyve Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Dyve Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

DYV700

Gout

Phase 2

Clinical Trials (1)

NCT04130204Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

Phase 2

Help build intelligence for Dyve Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage biotech focused on topical neurology with DYV700 in Phase 2 for gout, offering ground-floor opportunity in an underpenetrated modality
Camarillo, CA location provides access to West Coast biotech ecosystem and established pharma infrastructure
Specialized focus on topicals represents differentiated therapeutic approach with potential for reduced systemic toxicity

Watch Out For

Zero active job openings at time of analysis suggests company is not actively hiring or is in wind-down phase
Single Phase 2 program with minimal published data (0 publications) indicates early, unvalidated science with high clinical failure risk
Missing data on funding, employee count, and financial position raises questions about capitalization and runway

Generated by Claude from Dyve Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Metabolic Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Metabolic Diseases

1 pipeline

Marketed

Pipeline